CHM hasn't got the funds, simple. Another huge CR would have been necessary. That way the $4.4m can be claimed as R&D by IMU providing CHM with cash but paying roughly just $3m or so in reality. At least here Hopper applied something smart.
JC is behind that move, she is a CD19 guru. IMU now got the new licence for peanuts and can use the experts for " free ". I would hug PH if there wasn't that stupid discount over at IMU.
IMU / CHM now got 2 blood cancer platforms. CD19 and NK.
Pretty sure one day both will be merged. As the above $4.4m transfer shows, leaving them separate on paper for the time being seems to be the optimal strategy. That doesn't stop the experts to work on either projects.
If one believes in a product and knows it is of outstanding quality it can be sold at fair value. He chose discount over value.
Anyway, it is what it is, let's make the best out of it.
GLTA
CHM Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)